Annual Congress Berlin 2008

Saturday, 04.10.2008
Sunday, 05.10.2008
Monday, 06.10.2008
Tuesday, 07.10.2008
Wednesday, 08.10.2008

Citations should be made in the following way: Authors. Title. Eur Respir J 2008; 32: Suppl. 52, abstract number.

Material from 2008:

3952 Abstracts
658 Slide presentations
316 Webcasts
96 Handouts
1824 e-posters
316 Multimedia files

Material from 2008: Show

Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis

Oral Presentation
Chairs: G. B. Migliori (Tradate, Italy), R. Loddenkemper (Berlin, Germany)

Download all media

Second-line injectables: are they essential to treat MDR/XDR-TB cases? G. B. Migliori, R. Muetterlein, G. Sotgiu, G. De Iaco, K. Kliiman, O. Toungoussova, J. Ortmann, H. Hoffmann, E. Girardi, F. Lauria, C. Lange, TBNET Study Group (Tradate, Sassari, Sondalo, Cassano delle Murge, Rome, Italy; Parsberg, Bad Lippspringe, Gauti
Treatment outcomes of the use of moxifloxacin in management of patients with XDR-TB in Tomsk Oblast of the Russian Federation T. Tonkel, S. Mishustin, A. Strelis, G. Yanova, N. Chukova, A. Yedilbayev (Tomsk, Russian Federation; Boston, MA, United States Of America)
Increasing anti-tuberculosis drug resistance in the UK J. Watson, M. Kruijshaar, F. Drobniewski, J. Magee, G. Smith, I. Abubakar (London, Newcastle, Birmingham, United Kingdom)
Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial A. Abu-Hussein, A. H. Mahmoud, S. Al-Ashmawy, M. Wafae, S. Abdalla (Tanta, Cairo, Egypt)
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study A. Vilarica, C. Gomes, J. Pina (Lisboa, Portugal)
MDR- and XDR-TB in Germany B. Eker, J. Ortmann, G. B. Migliori, R. Muetterlein, R. Centis, A. Esselmann, B. Kretz, T. Schaberg, C. Schaudt, H. Hang, S. Ott, D. Kirsten, P. Hammel, R. Eberhardt, M. Pletz, H. Flick, S. Ruesch-Gerdes, P. Hannemann, S. Stenger, A. Paulick, K. D. Schnei
Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy G. B. Migliori, B. Eker, A. Esselmann, R. Centis, B. Kretz, J. Ortmann, G. De Iaco, C. Schaudt, A. Paulick, G. Enrico, N. Bevilacqua, H. Hang, C. Laumanns, D. Kirsten, T. Schaberg, C. Lange, TBNET Study Group (Tradate, Sondalo, Roma, Italy; Borstel, Heme
Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis H. S. Nam, W. J. Koh, S. H. Park, S. H. Kim, C. R. Ham, S. W. Um, G. Y. Suh, M. P. Chung, H. Kim, O. J. Kwon (Seoul, Republic Of Korea)